Completed NA INTERVENTIONAL NCT00076323

A Test to Predict the Hemolytic Potential of Drugs in G6PD Deficiency

A New Test to Predict the Hemolytic Potential of Drugs in G6PD Deficiency

Sponsor: Walter Reed Army Institute of Research (WRAIR)

Conditions Favism Glucosephosphate Dehydrogenase Deficiency

Interventions Primaquine

Updated 6 times since 2017 Last updated: Jul 26, 2010 Started: Dec 31, 2003 Completion: Nov 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Favism and Glucosephosphate Dehydrogenase Deficiency and is currently completed. Walter Reed Army Institute of Research (WRAIR) leads this study, which shows 6 recorded versions since 2003 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Jan 2026 — Present [monthly]

Completed NA
Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Dec 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Walter Reed Army Institute of Research (WRAIR)

Data source: Walter Reed Army Institute of Research (WRAIR)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Silver Spring, United States